Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest

Initial search results include only NCI-sponsored clinical trials. To search all trials, click the "REFINE SEARCH" button, scroll down to the Trial ID/Sponsor section and select the "All" check box in the Sponsor of Trial section.

View Content for:
Display:
?
Cancer Type/Condition:  Leukemia, acute lymphocytic (ALL), child
Country:  U.S.A.
Trial Type:  Treatment
Trial Status:  Active
Results 1-25 of 125 for your search:
Start Over
Combination Chemotherapy With or Without Rituximab in Treating Younger Patients With Stage III-IV Non-Hodgkin Lymphoma or B-Cell Acute Leukemia
Phase: Phase III, Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and under
Sponsor: NCI, Other
Protocol IDs: ANHL1131, NCI-2012-01963, CDR0000732604, IGR2009/1593, 2010-019224-31, U10CA098543, U10CA180886, COG-ANHL1131, NCT01595048
Total Therapy Study XVI for Newly Diagnosed Patients With Acute Lymphoblastic Leukemia
Phase: Phase III
Type: Treatment
Status: Active
Age: 18 and under
Sponsor: NCI, Other
Protocol IDs: TOTXVI, 5R01CA140729, 5F32CA141762, R37CA036401, 5R01CA090246, Aspar PK-PD-T16, NCI-2011-01254, NCT00549848
Myeloablative Hematopoietic Progenitor Cell Transplantation (HPCT) for Pediatric Malignancies
Phase: Phase III
Type: Treatment
Status: Active
Age: 21 and under
Sponsor: Other
Protocol IDs: SCT 0307, NCT00619879
Risk-Adapted Chemotherapy in Younger Patients With Newly Diagnosed Standard-Risk Acute Lymphoblastic Leukemia
Phase: Phase III
Type: Supportive care, Treatment
Status: Active
Age: 1 to < 10
Sponsor: NCI, Other
Protocol IDs: AALL0932, NCI-2011-02599, CDR0000683227, U10CA098543, COG-AALL0932, NCT01190930
Graft-Versus-Host Disease Prophylaxis in Treating Patients With Hematologic Malignancies Undergoing Unrelated Donor Peripheral Blood Stem Cell Transplant
Phase: Phase III
Type: Biomarker/Laboratory analysis, Supportive care, Treatment
Status: Active
Age: not specified
Sponsor: NCI, Other
Protocol IDs: 2448.00, NCI-2010-02035, P01CA018029, P30CA015704, NCT01231412
Combination Chemotherapy in Treating Young Patients With Newly Diagnosed High-Risk Acute Lymphoblastic Leukemia
Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 1 to 30
Sponsor: NCI, Other
Protocol IDs: AALL1131, NCI-2011-03797, CDR0000706370, U10CA098543, COG-AALL1131, NCT01406756
P3 Study of Umbilical Cord Blood Cells Expanded With MPCs for Transplantation in Patients With Hematologic Malignancies
Phase: Phase III
Type: Treatment
Status: Active
Age: 65 and under
Sponsor: Pharmaceutical / Industry
Protocol IDs: CB-AB006, 2012-0166, NCT01854567
Combination Chemotherapy With or Without Bortezomib in Treating Younger Patients With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia or Stage II-IV T-Cell Lymphoblastic Lymphoma
Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 2 to 30
Sponsor: NCI
Protocol IDs: NCI-2014-00712, AALL1231, U10CA180886, U10CA098543, NCT02112916
Reduced Intensity Transplant Using Extracorporeal Photopheresis
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 and under
Sponsor: Other
Protocol IDs: ECP RIT, NCT00179790
Fludarabine Phosphate, Cyclophosphamide, Total-Body Irradiation, and Donor Bone Marrow Transplant Followed by Donor Natural Killer Cell Therapy, Mycophenolate Mofetil, and Tacrolimus in Treating Patients With Hematologic Cancer
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: Any age
Sponsor: NCI, Other
Protocol IDs: 2230.00, NCI-2010-00106, P01CA078902, P30CA015704, FHCRC-2230.00, IR-6771, NCT00789776
Allogeneic Transplantation for Pediatric Leukemias With Unrelated Donors
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 21 and under
Sponsor: Other
Protocol IDs: SCT 0208, NCT00679536
Trial of Nelarabine, Etoposide and Cyclophosphamide in Relapsed T-cell ALL and T-cell LL
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 1 to 21
Sponsor: Other
Protocol IDs: T2008-002, NCT00981799
Reduced Intensity, Partially HLA Mismatched BMT to Treat Hematologic Malignancies
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 6 montha to 70
Sponsor: Other
Protocol IDs: J1055, NA_00039823, NCT01203722
Shorter Course Tacrolimus After Nonmyeloablative, Related Donor BMT With High-dose Posttransplantation Cyclophosphamide
Phase: Phase II, Phase I
Type: Supportive care, Treatment
Status: Active
Age: 6 months to 85
Sponsor: Other
Protocol IDs: J1151, NA_00048378, NCT01342289
A Pilot Study of Decitabine and Vorinostat With Chemotherapy for Relapsed ALL
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 21 and under
Sponsor: Other
Protocol IDs: T2009-003, NCT01483690
Phase I/II MAHCT w/ TCell Depleted Graft w/ Simultaneous Infusion Conventional and Regulatory T Cell
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 13 to 60
Sponsor: NCI, Other
Protocol IDs: BMT236, SU-09142011-8407, NCT01660607
Mitoxantrone and Clofarabine for Treatment of Recurrent NHL or Acute Leukemia
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 30 and under
Sponsor: Other
Protocol IDs: NYMC 542, L 10, 819, NCT01842672
Safety and Tolerability of HSC835 in Patients Undergoing Single Umbilical Cord Blood Transplant
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: Not specifiec
Sponsor: Pharmaceutical / Industry
Protocol IDs: CHSC835X2202, NCT01930162
A Pediatric and Young Adult Trial of Genetically Modified T Cells Directed Against CD19 for Relapsed/Refractory CD19+ Leukemia
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 1 to 26
Sponsor: Other
Protocol IDs: PLAT-02, NCT02028455
Haplo-identical SCT for HR Hematologic Malignancies w/Post-Transplant In-Vivo T-cell Depletion
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: Not specified
Sponsor: Other
Protocol IDs: SCT 0813 Haplo, NCT02053545
CD34+ (Malignant) Stem Cell Selection for Patients Receiving Allogenic Stem Cell Transplant
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: Under 22
Sponsor: Other
Protocol IDs: AAAK8060, NCT02061800
Safety Study of Gene Modified Donor T-cells Following TCR Alpha Beta Depleted Stem Cell Transplant
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 3 months to 21 years
Sponsor: Pharmaceutical / Industry
Protocol IDs: BP-004, NCT02065869
BMN-673 and Temozolomide in Treating Younger Patients With Refractory or Recurrent Malignancies
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 13 months to 30 years
Sponsor: NCI
Protocol IDs: NCI-2014-00804, ADVL1411, UM1CA097452, NCT02116777
Selinexor With Fludarabine and Cytarabine for Treatment of Refractory or Relapsed Leukemia or Myelodysplastic Syndrome
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 24 and under
Sponsor: Other
Protocol IDs: SELHEM, NCI-2014-01704, NCT02212561
Study of Carfilzomib in Combination With Dexamethasone, Mitoxantrone, PEG-asparaginase, and Vincristine in Children With Relapsed or Refractory Acute Lymphoblastic Leukemia
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and under
Sponsor: Pharmaceutical / Industry
Protocol IDs: CFZ008, 2014-001633-84, NCT02303821
Start Over